Full Press Release Details
Life Sciences Announces Purchase of Common Shares by Chief Medical Officer
York, September 9, 2022 - Tiziana Life Sciences Ltd.(Nasdaq: TLSA) ("Tiziana" or the "Company"),
a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified
that Matthew Davis, its Chief Medical Officer, purchased 100,000 common shares at $0.76 per share.
Tiziana Life Sciences
Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies
to enable alternative routes of immunotherapy. Tiziana's innovative nasal, oral and inhalation approaches in development have the
potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's
two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated
a favorable safety profile and clinical response in patients in studies to date. Tiziana's technology for alternative routes of
immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
Malik, Business Development,
and Investor Relations Manager
email: info@tizianalifesciences.com